Home › NCT05758701
CT TAVR Abdomen Study
Dual Energy CT Decreased IV Contrast Dose Imaging for TAVR
Who can join
Ages 18 to 88 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * scheduled to receive TAVR abdominal CT Exclusion Criteria: * cannot undergo CT scan * Allergy to intravenous contrast not controlled by steroids or benadryl * GFR\<30
About the study
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.
What is being tested
- Iodinated Contrast Agent (Omnipaque) (combination product)
- Dual Energy CT (device)
Sponsor: University of Maryland, Baltimore · Participants: 164 · Started: Sep 19, 2023
Contact the study team
- Vikas Kundra, M.D., Ph.D · Phone: 410-328-3477
- Rosy Njonkou, M.S. · Phone: 410-706-0943
Official record on ClinicalTrials.gov — NCT05758701
Locations in the U.S.
| Maryland | University of Maryland Medical Center, Baltimore |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.